uniQure produces its AAV-based gene therapies in our own facilities with our proprietary manufacturing process, which uses insect cells and baculoviruses, a common family of viruses found in invertebrates. An overview of our key patent portfolio can be found here.
The Company's manufacturing capabilities may also make us an attractive collaborator for academic research institutions and biotechnology and pharmaceutical companies seeking to advance their programs into larger, late-stage clinical trials that require commercial-scale manufacturing.
uniQure’s facility in Lexington, Mass. is one of the largest, most versatile gene therapy manufacturing facilities in the world. uniQure has invested more than $25 million in designing, constructing and equipping our 55,000 square foot facility with state-of-the-art laboratories and commercial-scale production capabilities. The facility offers GMP production capabilities to support all of our existing programs, with flexibility to expand further.
uniQure is committed to manufacturing excellence in gene therapy, and we believe that our leading manufacturing capabilities provide us a significant competitive advantage in rapidly delivering gene therapies to patients.
In March 2017, uniQure was recognized by Frost & Sullivan as a 2017 Manufacturing Leadership Awards winner for outstanding achievement in Engineering & Production Technology Leadership.